MNPR vs TIPT Comparison

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Tiptree Inc is a United States-based company that provides specialty insurance products and related services. It has two reportable segments: Insurance and Mortgage. The company generates the majority of its revenue from the Insurance Segment, which is engaged in designing, marketing, and underwriting specialty property and casualty insurance products incorporating value-added coverages and services for select target markets or niches. The Mortgage segment originates loans for sale to institutional investors, including GSEs and FHA/VA, and services loans on behalf of Fannie Mae, Freddie Mac, and Ginnie Mae.